Division of Boston Scientific Corp.
Latest From Xlumena Inc.
Bristol is trying to build off of Eliquis momentum, signing a cardiovascular gene therapy deal with uniQure; Celgene capitalized on build-to-buy model and exercised option for Quanticel. Biopharma financing was down by almost $3 billion, while device fundraising was slightly up.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Research/Analytical, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March–April 2015.
In the $62.5 million-plus-milestone deal Boston Scientific gets Xlumena's Axios and Hot Axios stent and delivery systems for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts. The products fit alongside Boston's Expect endoscopic ultrasound aspiration needles.
Diagnostic Imaging Equipment & Supplies
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
Greg Patterson, Pres. & CEO
Kenneth F Binmoeller, MD, CMO
Peter Brown, VP, R&D
- Contact Info
Phone: (650) 961-9900
453 Ravendale Dr., Ste. H
Mountain View, CA 94043
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.